Brickell Biotech Inc (BBI) Stock
BBI is no longer traded. Brickell Biotech was delisted from the Nasdaq in April 2024.
Prices on this page are historical; the last trade was April 19, 2024 at $0.90.
Brickell Biotech stock price history
BBI final trading statistics
- Final close
- $0.90
- Final trading day
- Apr 19, 2024
- Market cap at delisting
- $6.75M
- Shares outstanding
- 2.87M
- Final 52-week range
- $0.45 – $1.10
- Avg. volume (final 3 mo.)
- 14,690
- All-time high (split-adj.)
- $86940.00 · Feb 2000
- All-time low (split-adj.)
- $0.49 · May 2023
- Return since IPO
- -100.0%
- Beta
- 0.08
- Book value / share
- $5.81
- Price / book
- 0.15
Brickell Biotech annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $404.0K | -$39.5M | -$23.85 |
| FY2020 | $1.82M | -$20.9M | -$15.30 |
| FY2019 | $7.92M | -$23.9M | -$5.26 |
| FY2018 | $1.62M | -$16.3M | -$5.25 |
| FY2017 | $13.82M | -$13.0M | -$3.91 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Brickell Biotech Inc
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Brickell Biotech stock FAQ
What happened to Brickell Biotech stock?
Brickell Biotech stock was delisted from the Nasdaq. Its final close was $0.90 on April 19, 2024.
Is BBI stock still trading?
No. BBI was delisted from the Nasdaq in April 2024 and no longer trades on a U.S. exchange.
What was the last price of BBI stock?
BBI closed at $0.90 on its final trading day, April 19, 2024, for a market value of about $6.75M.
What were Brickell Biotech's revenue and earnings in its last full fiscal year?
Brickell Biotech reported revenue of $404.0K and net income of -$39.5M in fiscal 2021, its last full year as a public company.
When did Brickell Biotech go public?
Brickell Biotech Inc stock began trading on March 15, 1993.